Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy

Patent metadata

Field	Value
Publication number	US-12465591-B2
Application number	US-201917286529-A
Country	US
Kind code	B2
Filing date	Oct 18, 2019
Priority date	Oct 19, 2018
Publication date	Nov 11, 2025
Grant date	Nov 11, 2025

Abstract

The present invention relates to use of a carbamate compound of Formula 2 for the purpose of preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy by administering a pharmaceutical composition comprising a carbamate compound of Formula 2.

First claim

What is claimed is:

1 . A method for alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy, comprising:
administering to a subject in need thereof a therapeutically effective amount of a carbamate compound which is carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl-ethyl ester of the following Formula 2, or a pharmaceutically acceptable salt or hydrate thereof:

2 . The method according to claim 1 , wherein the subject is a mammal.

3 . The method according to claim 1 , wherein the therapeutically effective amount of the carbamate compound of Formula 2 is 50 to 500 mg based on a free form once-daily administration.

4 . The method according to claim 3 , wherein the therapeutically effective amount of the carbamate compound of Formula 2 is 50 to 400 mg based on a free form once-daily administration.

5 . The method according to claim 4 , wherein the therapeutically effective amount of the carbamate compound of Formula 2 is 50 to 300 mg based on a free form once-daily administration.

6 . The method according to claim 5 , wherein the therapeutically effective amount of the carbamate compound of Formula 2 is 50 to 200 mg based on a free form once-daily administration.

7 . The method according to claim 1 , wherein the diabetic peripheral neuropathy is painful diabetic peripheral neuropathy, diabetic autonomic neuropathy or both.

8 . The method according to claim 1 , wherein the chemotherapy-induced peripheral neuropathy is caused by a chemotherapeutic agent which is one or more selected from the group consisting of platinum-based drugs, taxanes, and vinca alkaloids.

9 . The method according to claim 1 , wherein the carbamate compound of Formula 2 is administered orally, parenterally, intravenously, intramuscularly, subcutaneously, or rectally.

Assignees

• Sk Biopharmaceuticals Co Ltd

Inventors

• Hwang Sun Gwan
• Lee Ji Won

Classifications

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• A61K31/41 Primary

  having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title

• A61K45/06 Primary

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title